Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that ...

Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

A weekly newsletter focusing on the most important news in health and biotech. Founded at the Massachusetts Institute of ...

A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...

Biotechnology has long relied on a handful of model microorganisms, such as Escherichia coli and Saccharomyces cerevisiae, whose genetics and physiology are ...

Explore the revolutionary potential of biotechnology and gene editing, alongside crucial ethical considerations and ...

Explore advancements in biotechnology, from gene editing's ethical dilemmas to synthetic biology's commercial potential and ...